The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer
Year: 2006
Type: article
Abstract: BACKGROUND: The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial. METHODS: The multivariate associations between 3-month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3-month change in HGB level and time-to-event outcomes, including overall survival and progression-free survival, were evaluated by using proportional hazards regression models. RESULTS: Quartiles of baseline HGB levels were < or =12.0 g/dL, from 12.1 to 13.7 g/dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); however, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who had baseline HGB levels <12 g/dL and decreased 1.04 g/dL (SD, 1.28 g/dL) in patients who had baseline HGB levels > or =12 g/dL. After adjusting for potential confounders, including baseline HGB level, a decline in HGB after 3 months of ADT was associated independently with shorter survival (hazards ratio [HR], 1.10 per 1 g/dL decline; P = .0035) and shorter progression-free survival (HR, 1.08 per 1 g/dL decline; P = .013). An unexpected finding was that the effect of baseline HGB on overall and progression-free survival varied significantly by race. CONCLUSIONS: In a sample of men with newly diagnosed, metastatic prostate cancer, a decline in HGB level after 3 months of ADT was associated with shorter survival and progression-free survival after adjusting for disease status and other baseline covariates. Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression-free survival varied significantly by race.
Source: Cancer
DOI: 10.1002/cncr.22029
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: SOUTHWEST ONCOLOGY GROUP, G1033243903, Southwest Oncology Group, KINGS COUNTY MINORITY BASED CLINICAL ONCOLOGY PROGRAM, G117886320, G1194379741, G1202672505, G1235982543, SOUTHWEST ONCOLOGY GROUP, G1268312386, SAN JOAQUIN VALLEY COMMUNITY CLINICAL ONCOLOGY PROGRAM, G1375689152, G1392966516, CALIFORNIA HEALTHCARE SYSTEM CCOP, G1469275664, G157871073, COOPERATIVE STUDY OF CANCER CHEMOTHERAPY, G1790576020, G1794831901, G1911575068, G1958973285, G2064543036, SOUTHWEST ONCOLOGY GROUP, G217018306, G2397742718, G2419449687, ALLEGHENY COMMUNITY CLINICAL ONCOLOGY PROGRAM, G2562936776, G2651303880, G268786457, WESTERN ONCOLOGY RESEARCH CONSORTIUM, G2745671310, G2779306227, G2780474162, Southwest Oncology Group, Southwest Oncology Group U10 Member Site, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, G3041257426, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G313314762, G3334379738, G3337849518, G3350348941, G3411601502, G345775953, City of Hope Southwest Oncology Group Clinical Trials, G3705794112, COMMUNITY CLINICAL ONCOLOGY PROGRAM, G413878341, Southwest Oncology Group, Dayton Clinical Oncology Program, SOUTHWEST ONCOLOGY GROUP--CLINICAL TRIALS, G425646771, Southwest Oncology Group, CENTRAL LOS ANGELES COMMUNITY CLINICAL ONCOLOGY PROGRAM, G4292856267, SOUTHWEST ONCOLOGY GROUP, G4527800867, G461382845, SOUTHWEST ONCOLOGY GROUP, COMMUNITY CLINICAL ONCOLOGY PROGRAM, G4935167430, SOUTHWEST ONCOLOGY GROUP, G5125348268, G543303160, G5504618518, SOUTHWEST ONCOLOGY GROUP CA13612, COMMUNITY CLINICAL ONCOLOGY PROGRAM, UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM, G591690631, SOUTHWEST ONCOLOGY GROUP, G6109875642, Southwest Oncology Group Treatment Grant, SOUTHWEST ONCOLOGY GROUP, Southwest Oncology Group, Gulf Coast MBCCOP, SOUTHWEST ONCOLOGY GROUP, SOUTHWEST ONCOLOGY GROUP STUDIES, University of Colorado Southwest Oncology Group, G7061256793, NORTHWEST COMMUNITY CLINICAL ONCOLOGY PROGRAM, G712978930, CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STUDY, Community Clinical Oncology Program, G758084519, Virginia Mason Community Clinical Oncology Program, G763325562, SOUTHWEST ONCOLOGY GROUP, Western Regional Community Clinical Oncology Program, ST Louis-Cape Girardeau CCOP, SOUTHWEST ONCOLOGY GROUP (UTAH), G860872252, G869870603, SOUTHWEST ONCOLOGY GROUP, PARTICIPATE AS MEMBER OF SOUTHWEST ONCOLOGY GROUP, G933283670, G945297361, G960417071, G971274320, Southwest Oncology Group/University of California, Davis
OpenAlex ID: W2148320338